A short-term curative observation of nimotuzumab combined with concurrent intensity-modulated radiotherapy and chemotherapy in the treatment of locally advanced cervical cancer
10.3760/cma.j.issn.1673-422X.2015.08.008
- VernacularTitle:尼妥珠单抗联合同期放化疗治疗局部晚期宫颈癌的近期疗效观察
- Author:
Churong WU
;
Wubing TANG
;
Wen YANG
;
Yongfa CHEN
;
Xingxi PAN
;
Yongsheng ZHANG
;
Hua YANG
;
Haichun LIANG
;
Hongdong HUANG
- Publication Type:Journal Article
- Keywords:
Uterine cervical neoplasms;
Radiotherapy;
Drug therapy;
Antibodies,monoclonal;
Nim-otuzumab
- From:
Journal of International Oncology
2015;(8):589-592
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the efficacy and adverse effects of nimotuzumab combined with chemotherapy and radiotherapy in the treatment of locally advanced cervical cancer.Methods Sixty patients with stage Ⅲ cervical cancer by the histopathologic diagnosis were collected,and they were randomly divided into two groups using the random number table method.The control group (n =30)using intensity-modulated radiotherapy,intracavitary afterloading therapy and periodic chemotherapy,the observation group (n =30)in addition to the intensity-modulated radiotherapy,intracavitary afterloading therapy and periodic chemotherapy, the nimotuzumab (200 mg)was given to the patients before weekly radiotherapy.All patients were received 6 to 7 times of treatment.Results The curative effects of all the patients were evaluated after radiotherapy 3 months.In the observation group,there were 20 cases of CR,5 cases of PR,4 cases of SD,1 case of PD,the total effective rate (CR +PR)was 83.3%.In the control group,there were 1 8 cases of CR,3 cases of PR,6 cases of SD,3 cases of PD,the total effective rate was 70.0%.The difference was statistically significant (χ2 =8.356,P <0.05).The main adverse reactions in the observation group and control group included slight radioactive proctitis (1 6.7% vs 1 3.3%),radioactive cystitis (1 0.0% vs 1 0.0%),nausea and vomiting (50.0% vs 46.7%),reduction of white blood cells (40.0% vs 43.3%),with no significant differences (χ2 =3.357,P =0.71 9;χ2 =2.71 7,P =0.925;χ2 =5.882,P =0.623;χ2 =4.728,P =0.687).There were no skin rashes and allergic reactions.Conclusion Nimotuzumab can enhance the locally stage cervical cancer patients′sensitivity on radiotherapy,which can increase the efficacy and doesn′t increase adverse
reaction obviously.
